Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03505723 · ClinicalTrials.gov registry record · Phase 3
PeriOperative ISchemic Evaluation-3 Trial
A Phase 3 study, sponsored by Population Health Research Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 9,535
- Enrollment target
NCT03505723 is a Phase 3 study that has completed, run by Population Health Research Institute. The registered enrollment target is 9,535 participants.
The verdict
NCT03505723, a Phase 3 study, has completed, sponsored by Population Health Research Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 9,535 participants
- Enrollment target
Study Summary
This study is a multicentre, international, randomized controlled trial of tranexamic acid (TXA) versus placebo and, using a partial factorial design, of a perioperative hypotension-avoidance versus hypertension-avoidance strategy.
Interventions
- DRUG Tranexamic Acid
- DRUG Placebo (Saline)
- OTHER Perioperative hypotension-avoidance strategy
- OTHER Perioperative hypertension-avoidance strategy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,535 participants |
| Start Date | 2018-06-27 |
| Est. Completion | 2023-02-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03505723
The ClinicalTrials.gov registry entry for NCT03505723 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 9,535 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Population Health Research Institute, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Tranexamic Acid is the first listed.
NCT03505723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03505723 about?
NCT03505723 is a clinical study titled "PeriOperative ISchemic Evaluation-3 Trial". This study is a multicentre, international, randomized controlled trial of tranexamic acid (TXA) versus placebo and, using a partial factorial design, of a perioperative hypotension-avoidance versus hypertension-avoidance strategy.
What is the current status of trial NCT03505723?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 9,535 participants. The study started on 2018-06-27. Estimated completion is 2023-02-03.
What interventions are being tested in trial NCT03505723?
The interventions under investigation include: Tranexamic Acid (DRUG), Placebo (Saline) (DRUG), Perioperative hypotension-avoidance strategy (OTHER), Perioperative hypertension-avoidance strategy (OTHER).
Who is sponsoring clinical trial NCT03505723?
This trial is sponsored by Population Health Research Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.